Agios Pharmaceuticals Inc Shares Close the Week 25.6% Higher - Weekly Wrap

The company saw its shares close the week 25.6% higher than last week, with trading volume higher than its 30 day average.

Jun 24, 2022 by Kwhen Finance Editors

Agios Pharmaceuticals Inc Shares Close the Week 25.6% Higher - Weekly Wrap
Agios Pharmaceuticals Inc (AGIO) shares closed this week 25.6% higher than it did at the end of last week. The stock is currently down 31.3% year-to-date, down 60.1% over the past 12 months, and down 61.9% over the past five years. This week, the Dow Jones Industrial Average rose 2.5%, and the S&P 500 rose 3.6%.

Trading Activity

  • Shares traded as high as $22.61 and as low as $17.38 this week.
  • Shares closed 61.5% below its 52-week high and 34.7% above its 52-week low.
  • Trading volume this week was 40.2% lower than the 10-day average and 0.7% lower than the 30-day average.
  • Beta, a measure of the stock’s volatility relative to the overall market stands at 1.3.

Technical Indicators

  • The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.
  • MACD, a trend-following momentum indicator, indicates an upward trend.
  • The stock closed below its Bollinger band, indicating it may be oversold.

Fundamentals & Catalysts

  • Over the past 12 months the company generated $-354,185,000 in earnings before interest and taxes from $116 million in revenue. It currently holds $2 billion in cash and $96 million in debt.
  • Its forward price-to-earnings (P/E) ratio of 0 is lower than its current P/E ratio of 0.77, implying that analysts are expecting an increase in earnings.
  • The company's price/earnings-to-growth ratio (PEG Ratio), a widely used indicator of a stock's true value while also factoring in expected earnings growth, currently stands at 0.00. A fairly valued company should have a PEG ratio of 1.0. When a company's PEG exceeds 1.0, it's considered overvalued while a stock with a PEG of less than 1.0 is considered undervalued.
  • The company's debt-to-equity ratio, which measures the extent to which it finances its operations through debt, currently stands at 1.08 which means it currently has $1.08 of debt for every $1 of equity. Generally speaking, a debt to equity ratio below 1.0 is seen as relatively safe, while ratios of 2.0 or higher would be considered risky. Some industries are known for having much higher debt to equity ratios than others.
  • The company's price-to-book ratio, which measures the market's valuation of a company relative to its book value, currently stands at 1.50. This means that the stock is trading at a premium of 2 times relative to the company's book value which reflects the total value of a company's assets that shareholders of that company would receive if the company were to be liquidated.
  • The company's price-to-sales ratio, which shows how much the market values every dollar of the company's sales, currently stands at 29.58.
  • The company's enterprise value-to-revenue multiple, which is often used to determine a company's valuation in the case of a potential acquisition, currently stands at 9.47.

P/E

0.77

EBITDA

$-354,185,000

P/Book

1.50

Mkt Cap

$1B

P/Sales

29.58

Revenue

$116M

EPS (TTM)

24.93

PEG Ratio

0.00

EV/Revenue

9.47

Total Cash

$2B

Debt/Equity

1.08

Forward P/E

0.00

Current Debt

$96M

Gross Profit

$113M

Dividend Date

-

Earnings Date

2022-07-28

Profit Margin

13.67

Revenue/Share

1.89

Total Revenue

$116M

Enterprise Val

$1B

Put/Call Ratio

1.23

Revenue/Employee

216600.75

Market Comparative Performance

  • The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis
  • The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis
  • The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis
NameDoD %ΔYTD %Δ1 Yr %52-Week H %52-Week L %
Agios Pharmaceuticals Inc6.1-31.3-60.1-63.129.0
Dow Jones Industrial Average2.7-14.8-7.8-15.54.3
S&P 500 Index3.2-19.8-9.3-19.95.3
Health Care1.6-9.21.1-10.68.9

Peer Group Comparative Performance

  • The company's stock price performance year-to-date lags the peer average by 4994.6%
  • The company's stock price performance over the past 12 months lags the peer average by -619.4%
  • The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -99.1% lower than the average peer.
NameMKT CAP (USD)P/EYTD %Δ1 Yr %Δ52-Week H %52-Week L %
Agios Pharmaceuticals IncAGIO0.8-31.3-60.1-63.129.0
Peer AvgN/A87.6-0.611.6-13.333.5
Lilly(Eli) & CoLLY50.518.841.7-1.846.9
Pfizer Inc.PFE11.6-11.336.1-16.335.5
Glaxosmithkline plc - ADRGSK16.31.315.4-7.118.6
Biomarin Pharmaceutical Inc. - Registered SharesBMRN408.3-1.73.7-9.221.0
Exelixis IncEXEL23.921.6-2.8-7.140.2
Xencor IncXNCR14.9-32.4-24.7-38.438.7

This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.

Was this content valuable for you?

Tags: